MX2020008680A - Terapia de combinacion con apilimod y agentes glutamatergicos. - Google Patents

Terapia de combinacion con apilimod y agentes glutamatergicos.

Info

Publication number
MX2020008680A
MX2020008680A MX2020008680A MX2020008680A MX2020008680A MX 2020008680 A MX2020008680 A MX 2020008680A MX 2020008680 A MX2020008680 A MX 2020008680A MX 2020008680 A MX2020008680 A MX 2020008680A MX 2020008680 A MX2020008680 A MX 2020008680A
Authority
MX
Mexico
Prior art keywords
apilimod
combination therapy
glutamatergic agents
glutamatergic
agents
Prior art date
Application number
MX2020008680A
Other languages
English (en)
Inventor
Henri Lichenstein
Sean Landrette
Jonathan M Rothberg
Peter R Young
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of MX2020008680A publication Critical patent/MX2020008680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones y métodos relacionados con el uso de apilimod en combinación con agentes glutamatérgicos para el tratamiento de enfermedades y trastornos neurológicos y para el tratamiento de cáncer.
MX2020008680A 2018-02-21 2019-02-20 Terapia de combinacion con apilimod y agentes glutamatergicos. MX2020008680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633335P 2018-02-21 2018-02-21
PCT/US2019/018662 WO2019164861A1 (en) 2018-02-21 2019-02-20 Combination therapy with apilimod and glutamatergic agents

Publications (1)

Publication Number Publication Date
MX2020008680A true MX2020008680A (es) 2020-09-25

Family

ID=65729429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008680A MX2020008680A (es) 2018-02-21 2019-02-20 Terapia de combinacion con apilimod y agentes glutamatergicos.

Country Status (12)

Country Link
US (3) US10751345B2 (es)
EP (1) EP3755332A1 (es)
JP (2) JP7354123B2 (es)
KR (1) KR20200138714A (es)
CN (1) CN111801098A (es)
AU (1) AU2019223014B2 (es)
BR (1) BR112020016256A2 (es)
IL (1) IL276609A (es)
MX (1) MX2020008680A (es)
RU (1) RU2020130837A (es)
TW (1) TW202000205A (es)
WO (1) WO2019164861A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023324A1 (en) * 2018-07-22 2020-01-30 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
HUE058320T2 (hu) 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
WO2021252895A2 (en) * 2020-06-11 2021-12-16 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
CA3187323A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
WO2022197767A1 (en) * 2021-03-17 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for improving survival in lung cancer patients via ketamine oncoprotection
WO2022261499A1 (en) * 2021-06-11 2022-12-15 AI Therapeutics, Inc. Stabilized apilimod compositions and uses thereof
WO2024015281A1 (en) * 2022-07-11 2024-01-18 AI Therapeutics, Inc. Apilimod combination therapy
WO2024015286A1 (en) * 2022-07-11 2024-01-18 AI Therapeutics, Inc. Apilimod combination therapy
WO2024107448A1 (en) * 2022-11-15 2024-05-23 Orphai Therapeutics Inc. Apilimod combination therapy
WO2024118515A1 (en) * 2022-11-28 2024-06-06 Orphai Therapeutics Inc. Pikfyve inhibitor combination therapy
WO2024191947A1 (en) * 2023-03-15 2024-09-19 Orphai Therapeutics Inc. Pikfyve inhibitor combination therapy
WO2025030033A1 (en) * 2023-08-03 2025-02-06 Orphai Therapeutics Inc. Apilimod compositions and methods of use

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (es) 1962-09-13
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
US4658019A (en) 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB2196003A (en) 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
AU5554190A (en) 1989-05-08 1990-11-29 Mark I. Farber Process and apparatus for the recovery of precious metals from slag, tailings and other materials
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (es) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
NZ258412A (en) 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
WO1995013069A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5597898A (en) 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
CA2187969C (en) 1995-10-17 2006-05-30 Dale L. Boger A template for solution phase synthesis of combinatorial libraries
US6190619B1 (en) 1997-06-11 2001-02-20 Argonaut Technologies, Inc. Systems and methods for parallel synthesis of compounds
US6242253B1 (en) 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same
US6001652A (en) 1998-09-18 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of cREL expression
US6384032B1 (en) 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
EP1185528A4 (en) 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
AU2002322478A1 (en) 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
MXPA04005181A (es) 2001-11-30 2005-06-17 Synta Pharmaceuticals Corp Compuestos de pirimidina.
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
TW200510394A (en) 2003-05-29 2005-03-16 Synta Pharmaceuticals Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
TWI359017B (en) 2003-11-10 2012-03-01 Synta Pharmaceuticals Corp Heteroaryl-hydrazone compounds
US20050282232A1 (en) 2003-11-10 2005-12-22 Rongzhen Lu Compositions and methods for modulating c-Rel-dependent cytokine production
EP1687002A4 (en) 2003-11-10 2008-07-23 Synta Pharmaceuticals Corp CONDENSED HETEROCYCLIC COMPOUNDS
AU2005244745B2 (en) 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
CN101035542A (zh) 2004-08-25 2007-09-12 默克公司 组蛋白脱乙酰基酶抑制剂
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
TW200630363A (en) 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
CA2587590A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
EA024161B1 (ru) 2006-07-12 2016-08-31 Юниверсити Оф Теннесси Рисерч Фаундейшн Фармацевтические композиции, содержащие замещенные ациланилиды
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
DE112012000404T5 (de) 2011-01-04 2014-04-17 Charitè Universitätsmedizin Berlin Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
RU2016134406A (ru) 2014-01-24 2018-03-01 Лэм Терапьютикс, Инк. Композиции апилимода и способы их применения
CN107206090A (zh) * 2014-11-07 2017-09-26 拉姆医疗公司 阿匹莫德在结肠直肠癌治疗中的用途
PL3215158T3 (pl) * 2014-11-07 2019-11-29 Ai Therapeutics Inc Apilimod do zastosowania do leczenia raka nerki
LT3220891T (lt) * 2014-11-21 2019-11-11 Biohaven Therapeutics Ltd Poliežuvinė riluzolio kompozicija
EA201791110A1 (ru) 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
WO2016112072A1 (en) 2015-01-07 2016-07-14 President And Fellows Of Harvard College Methods for treating or preventing ebolavirus or marburgvirus infections
WO2016118709A1 (en) 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
CA2999965A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
WO2016210372A2 (en) * 2015-06-25 2016-12-29 University Of Southern California Methods to treat neurological diseases
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
WO2017040971A1 (en) 2015-09-03 2017-03-09 Biomarin Pharmaceutical Inc. Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
LT3458053T (lt) * 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
US20180036420A1 (en) 2016-08-03 2018-02-08 Lam Therapeutics, Inc. Methods for enhancing the delivery of molecules across the blood brain barrier
US20180050041A1 (en) 2016-08-19 2018-02-22 Lam Therapeutics, Inc. Compositions and Methods for Treating Niemann Pick C Disease
BR112019007214A2 (pt) * 2016-10-12 2019-07-02 Ai Therapeutics Inc composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents

Also Published As

Publication number Publication date
US10751345B2 (en) 2020-08-25
AU2019223014A1 (en) 2020-08-20
EP3755332A1 (en) 2020-12-30
JP7354123B2 (ja) 2023-10-02
US20210077502A1 (en) 2021-03-18
CN111801098A (zh) 2020-10-20
CA3090807A1 (en) 2019-08-29
BR112020016256A2 (pt) 2020-12-15
IL276609A (en) 2020-09-30
WO2019164861A1 (en) 2019-08-29
JP2023179515A (ja) 2023-12-19
JP2021514358A (ja) 2021-06-10
AU2019223014B2 (en) 2024-10-17
US20230069069A1 (en) 2023-03-02
RU2020130837A3 (es) 2022-03-21
RU2020130837A (ru) 2022-03-21
US11957688B2 (en) 2024-04-16
US11439649B2 (en) 2022-09-13
TW202000205A (zh) 2020-01-01
US20190255061A1 (en) 2019-08-22
KR20200138714A (ko) 2020-12-10

Similar Documents

Publication Publication Date Title
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
SA520412543B1 (ar) تركيبات وطرائق لعلاج السرطان والاضطرابات المناعية باستخدام جراثيم الفيونيلّة
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2025009223A (es) Agentes de union a clec9a y su uso
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
PH12020551427A1 (en) Epinephrine spray formulations
WO2016025635A3 (en) Combination therapy for treating cancer
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
SMT202000305T1 (it) Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle
MX2021011488A (es) Compuestos y usos de estos.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
ZA202304965B (en) Combination therapy for treating cancer
MX2024006768A (es) Compuestos y usos de los mismos.
MX2020001727A (es) Terapia de combinacion.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2019013862A (es) Terapia de combinacion.